↑ Grab this Headline Animator

Genzymes Inorganic Growth Path and Strategic Initiatives Are Explored...

The US biotech industry is highly diversified, complex and fragmented with as many as 14,370 units in operation. The industry is experiencing double-digit growth along with consolidation, post the 2002 shakeout.



Genzyme is the fourth-largest biotech company in the world in revenue terms. The company has performed strongly on the back of its successful R&D initiatives. The one factor that clearly differentiates Genzyme from its peers is that around half of its sales revenue came from outside the US.



Genzyme's8217;s revenue increased at a CAGR of 30.87% over 2001-04. This was primarily on account of Renagel, Fabrazyme and Cerezyme sales. To offset dependence on these drugs, the company is now trying to grow inorganically by acquiring specialty in the oncology space.



Research and Markets (http://www.researchandmarkets.com/reports/c39992) has announced the addition of Genzyme: Company Analysis to their offering



This report provides a comprehensive analysis of Genzyme, Inc. It includes the company's8217;s organizational structure, description of its businesses and a vivid account of its competitive landscape. This is bolstered by key insights on its major competitors along with financial comparables. The study is conducted against the backdrop emerging trends in biotech and its future growth drivers. It highlights the current focus of the company on bringing products to market is driving the industry toward profitability.    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    




The report also explains Genzymes inorganic growth path and strategic initiatives. Genzyme is investing on restructuring and developing its manufacturing and R&D units across the globe. It has built a new research center in the UK and is improving quality at manufacturing facilities such as in Lyons. It is also investing in research infrastructure in the US.



Products Mentioned:

Therapeutics, Renal, Diagnostics, Biosurgery, Transplant & Immune Mediated Disorders



Countries Covered:

US, Europe



Companies Mentioned:

Crucell N.V. , Dyax Corp., Medtronic Inc., Cambridge Antibody Technology



Content Titles:

1. Corporate Overview



2. Business Description



3. SWOT Analysis



4. Key Business Strategies



5. Financial Performance



6. Competitive Landscape



7. Outlook



Appendix 1: Income Statement, 2002-2004

Appendix 2: Balance Sheet. 2002-2004

Appendix 3: Mergers & Acquisitions, 2000-2005



For more information visit http://www.researchandmarkets.com/reports/c39992



Laura Wood

Senior Manager

Research and Markets

Fax: +353 1 4100 980

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Cancer | Colon Cancer | diagnosed colon cancer |

---

4896 readers online...

, Local News